TNFRSF17 and plasma cell myeloma: These CD16 CARs were combined with the mAbs rituximab, SEA-BCMA, and trastuzumab for the treatment of CD20pos B cell lymphoma, BCMApos multiple myeloma, and HER2pos solid tumors, respectively (Table 1).